Visão geral da empresa
A biotechnology firm headquartered in Israel, Polyrizon Ltd. specializes in the development of medical device hydrogels formulated specifically as nasal sprays. The company leverages proprietary technology to create products designed to act as a barrier against various allergen particulates and viruses, addressing critical needs in respiratory health. Operating within the Healthcare sector and the Biotechnology industry, the firm focuses on advancing medical solutions that target specific biological mechanisms. With a market capitalization of $12.50M, the company operates on a micro-cap scale, indicating a smaller market presence compared to large-cap pharmaceutical peers. The annual revenue figure is unavailable, reflecting the typical characteristics of early-stage biotechnology entities where product commercialization or revenue generation has not yet materialized in the trailing twelve months. Furthermore, the employee count is listed as N/A, which suggests the organization maintains a lean operational structure or has not disclosed specific headcount data in public filings. The absence of reported revenue and the modest market cap highlight that the company is currently in a development phase rather than a mature profit-generating stage.
Saúde financeira
The company reports a net income of $-3,335,000 and an EBITDA of $-5,907,000 for the trailing twelve months, while revenue data remains unreported. The significant gap between the reported net income and the EBITDA loss indicates substantial non-operating expenses or specific accounting adjustments affecting the bottom line, though the lack of revenue figures makes a precise cost-of-goods-sold analysis impossible. Free cash flow stands at $-4,659,625, a metric that underscores the heavy capital consumption typical of R-intensive biotech firms burning through reserves to fund research and development. Despite the negative cash flow, the company holds a robust cash balance of $11.49M, which provides a substantial runway for operations without immediate need for external financing. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, a common characteristic for pre-revenue entities where traditional profitability ratios are mathematically undefined or zero due to lack of sales volume. The balance sheet appears highly conservative given the company possesses $11.49M in cash against $0 in debt, effectively eliminating leverage risk. This pristine debt profile is further evidenced by a debt-to-equity ratio that is N/A due to the absence of debt, reinforcing the entity's financial stability in a volatile sector. Additionally, the current ratio is an impressive 29.03, signaling exceptional short-term liquidity and the ability to cover liabilities with assets held at current replacement costs. Return on Equity is -25.4% and Return on Assets is -28.9%, figures that reflect the temporary nature of losses incurred during the investment phase rather than structural inefficiency.
Avaliação de valorização
The trailing twelve-month P/E ratio and forward P/E are both N/A, which is expected for a company with no earnings, implying that traditional earnings-based valuation models cannot be applied to forecast future profitability. The price-to-book ratio is 0.64, suggesting that the market values the company at significantly less than its tangible book value, a frequent occurrence in speculative biotech stocks where intangible assets like intellectual property are not fully captured on the balance sheet. Price-to-sales and EV/EBITDA metrics are either N/A or -0.33 respectively, providing limited conventional valuation context but highlighting the disconnect between market price and cash generation capacity. The stock has exhibited extreme volatility, trading between a 52-week low of $2.88 and a high of $2235.00, indicating a massive price range that defies standard technical analysis based on historical averages. The current price sits in a complex position relative to this range; while the exact percentage below the high cannot be calculated without the current spot price, the proximity to the 52-week low suggests the stock has experienced a severe correction from its peak. Beta is N/A, preventing a direct comparison of price volatility relative to the broader market index. The negative EV/EBITDA of -0.33 further reflects the entity's unprofitable status where enterprise value is calculated differently due to negative earnings power.
Growth & Income
Revenue growth and earnings growth rates are both N/A, as the company has not yet established a consistent track record of sales or earnings to calculate year-over-year changes. The absence of positive earnings growth is inherent to the business model, which prioritizes product development over immediate profit generation. Since the company does not pay dividends, the dividend yield and payout ratio are both N/A or 0.0%, meaning there is no distribution of cash to shareholders. Instead of paying dividends, the company reinvests all available cash flow back into its research and development efforts to advance its hydrogel technology. The overall growth and income profile is defined by a reliance on capital appreciation potential rather than current yield or consistent revenue expansion. Investors looking for income or steady revenue growth will not find these attributes in the current financial statement of Polyrizon Ltd. The company's strategy is purely growth-oriented in the traditional sense of expanding the pipeline, not expanding sales volume in the short term.